NatWest Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.29M | Buy |
45,148
+1,183
| +3% | +$166K | 1.36% | 30 |
|
|
2025
Q4 | $5.4M | Sell |
43,965
-44,590
| -50% | -$5.42M | 1.26% | 30 |
|
|
2025
Q3 | $9.83M | Sell |
88,555
-34,911
| -28% | -$3.97M | 2.43% | 18 |
|
|
2025
Q2 | $13.7M | Buy |
123,466
+2,968
| +2% | +$316K | 4.05% | 11 |
|
|
2025
Q1 | $13.5M | Buy |
120,498
+46,796
| +63% | +$4.83M | 3.98% | 9 |
|
|
2024
Q4 | $6.81M | Buy |
+73,702
| New | +$6.64M | 2.01% | 21 |
|
|
2023
Q2 | – | Sell |
-3,660
| Closed | -$304K | – | 46 |
|
|
2023
Q1 | $304K | Sell |
3,660
-787
| -18% | -$65.2K | 0.16% | 42 |
|
|
2022
Q4 | $382K | Sell |
4,447
-1,359
| -23% | -$108K | 0.22% | 43 |
|
|
2022
Q3 | $358K | Hold |
5,806
| – | – | 0.21% | 43 |
|
|
2022
Q2 | $359K | Sell |
5,806
-3,500
| -38% | -$217K | 0.2% | 40 |
|
|
2022
Q1 | $553K | Hold |
9,306
| – | – | 0.27% | 38 |
|
|
2021
Q4 | $676K | Hold |
9,306
| – | – | 0.35% | 33 |
|
|
2021
Q3 | $650K | Sell |
9,306
-24,497
| -72% | -$1.72M | 0.35% | 42 |
|
|
2021
Q2 | $2.33M | Buy |
33,803
+280
| +0.8% | +$18.7K | 1.2% | 26 |
|
|
2021
Q1 | $2.17M | Buy |
33,523
+134
| +0.4% | +$8.64K | 1.05% | 28 |
|
|
2020
Q4 | $1.95M | Sell |
33,389
-9,004
| -21% | -$543K | 0.72% | 36 |
|
|
2020
Q3 | $2.68M | Buy |
42,393
+5,471
| +15% | +$379K | 0.57% | 32 |
|
|
2020
Q2 | $2.84M | Buy |
36,922
+4,021
| +12% | +$308K | 0.77% | 26 |
|
|
2020
Q1 | $2.46M | Buy |
32,901
+4,216
| +15% | +$291K | 0.68% | 30 |
|
|
2019
Q4 | $1.86M | Buy |
28,685
+10,113
| +54% | +$659K | 0.4% | 40 |
|
|
2019
Q3 | $1.18M | Sell |
18,572
-79
| -0.4% | -$5.16K | 0.28% | 47 |
|
|
2019
Q2 | $1.26M | Buy |
18,651
+4,895
| +36% | +$322K | 0.23% | 47 |
|
|
2019
Q1 | $895K | Buy |
13,756
+1,170
| +9% | +$77.8K | 0.18% | 49 |
|
|
2018
Q4 | $787K | Buy |
12,586
+221
| +2% | +$15.4K | 0.17% | 51 |
|
|
2018
Q3 | $954K | Sell |
12,365
-271,087
| -96% | -$20.5M | 0.18% | 53 |
|
|
2018
Q2 | $20.1M | Buy |
283,452
+7,057
| +3% | +$498K | 4.13% | 10 |
|
|
2018
Q1 | $20.8M | Buy |
276,395
+7,978
| +3% | +$634K | 4.43% | 9 |
|
|
2017
Q4 | $19.2M | Buy |
268,417
+5,108
| +2% | +$388K | 4.32% | 11 |
|
|
2017
Q3 | $21.3M | Buy |
263,309
+25,822
| +11% | +$1.97M | 5.29% | 5 |
|
|
2017
Q2 | $16.8M | Buy |
237,487
+40,099
| +20% | +$2.67M | 3.89% | 10 |
|
|
2017
Q1 | $13.4M | Buy |
197,388
+14,273
| +8% | +$1M | 2.85% | 13 |
|
|
2016
Q4 | $13.1M | Buy |
183,115
+8,563
| +5% | +$636K | 3.45% | 9 |
|
|
2016
Q3 | $13.8M | Buy |
174,552
+76,691
| +78% | +$6.23M | 3.26% | 8 |
|
|
2016
Q2 | $8.16M | Buy |
97,861
+21,122
| +28% | +$1.87M | 2.06% | 14 |
|
|
2016
Q1 | $7.05M | Buy |
76,739
+5,635
| +8% | +$508K | 1.58% | 23 |
|
|
2015
Q4 | $7.2M | Sell |
71,104
-24,222
| -25% | -$2.52M | 1.45% | 23 |
|
|
2015
Q3 | $9.36M | Buy |
95,326
+91,659
| +2,500% | +$10.2M | 0.21% | 62 |
|
|
2015
Q2 | $430K | Sell |
3,667
-10,062
| -73% | -$1.1M | 0.01% | 277 |
|
|
2015
Q1 | $1.35M | Buy |
13,729
+6,407
| +88% | +$651K | 0.02% | 197 |
|
|
2014
Q4 | $690 | Buy |
+7,322
| New | +$757K | 0.01% | 264 |
|
|
2014
Q3 | – | Sell |
-6,116
| Closed | -$507K | – | 528 |
|
|
2014
Q2 | $507K | Sell |
6,116
-9,463
| -61% | -$737K | 0.02% | 345 |
|
|
2014
Q1 | $1.1M | Sell |
15,579
-117,076
| -88% | -$9.18M | 0.05% | 232 |
|
|
2013
Q4 | $9.96M | Buy |
132,655
+25,156
| +23% | +$1.75M | 0.25% | 92 |
|
|
2013
Q3 | $6.76M | Buy |
107,499
+98,839
| +1,141% | +$5.91M | 0.2% | 115 |
|
|
2013
Q2 | $444K | Buy |
+8,660
| New | +$451K | 0.01% | 621 |
|
Other funds holding GILD
VCM
VPM
NatWest Group's GILD Position: Q1 2026 in Review
NatWest Group increased its Gilead Sciences (GILD) stake by 2.7% in Q1 2026, buying an estimated $166K and bringing the position to 45,148 shares worth $6.29M. The position accounts for 1.36% of the portfolio, ranked #30.
NatWest Group first reported a position in GILD in Q2 2013 and has held it in 45 quarters since. The position peaked at $21.3M in Q3 2017. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- NatWest Group held 45,148 shares of Gilead Sciences worth $6.29M as of Q1 2026.
- NatWest Group bought 1,183 Gilead Sciences shares in Q1 2026, an estimated $166K.
- Gilead Sciences made up 1.36% of NatWest Group's portfolio in Q1 2026, its #30 holding.
- NatWest Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 45 quarters since.
- NatWest Group's Gilead Sciences position peaked at $21.3M in Q3 2017.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on NatWest Group's 13F filing for Q1 2026, filed 11 May 2026.